A detailed history of Stuart Chaussee & Associates, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Stuart Chaussee & Associates, Inc. holds 430 shares of LLY stock, worth $330,136. This represents 0.15% of its overall portfolio holdings.

Number of Shares
430
Previous 430 -0.0%
Holding current value
$330,136
Previous $389,000 2.31%
% of portfolio
0.15%
Previous 0.17%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 12, 2022

SELL
$234.69 - $291.66 $5,867 - $7,291
-25 Reduced 5.49%
430 $123,000
Q4 2021

Feb 07, 2022

BUY
$224.85 - $279.04 $12,366 - $15,347
55 Added 13.75%
455 $126,000
Q4 2020

Feb 03, 2021

SELL
$130.46 - $172.63 $866,515 - $1.15 Million
-6,642 Reduced 94.32%
400 $68,000
Q4 2017

Feb 02, 2018

BUY
$81.94 - $87.89 $577,021 - $618,921
7,042
7,042 $595,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $730B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Stuart Chaussee & Associates, Inc. Portfolio

Follow Stuart Chaussee & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stuart Chaussee & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stuart Chaussee & Associates, Inc. with notifications on news.